Achilles Therapeutics plc (ACHL)

NASDAQ: ACHL · IEX Real-Time Price · USD
2.52
0.11 (4.56%)
At close: May 20, 2022 4:00 PM
2.51
-0.01 (-0.40%)
After-hours:May 20, 2022 5:27 PM EDT

Company Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors.

The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer.

The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Achilles Therapeutics plc
CountryUnited Kingdom
Founded2016
IPO DateMar 31, 2021
IndustryBiotechnology
SectorHealth Care
Employees242

Contact Details

Address:
245 Hammersmith Road
London W6 8PW
United Kingdom
Phone44 20 8154 4600
Websiteachillestx.com

Stock Details

Ticker SymbolACHL
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$18.00
CIK Code1830749

Key Executives

NamePosition
Dr. Iraj AliChief Executive Officer and Director
Dr. Karl Peggs M.D.Founder and Chief Medical Officer
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.Founder
Dr. Charles Swanton FMEDSCI, M.D., Ph.D.Founder
Dr. Sergio A. Quezada Ph.D.Founder and Chief Scientific Officer
Robert CouttsChief Financial Officer
Lee M. SternVice President of Investor Relations and External Communications
Daniel HoodGeneral Counsel and Company Secretary
Julia WilsonHead of Communications
Tariq AhmedVice President of People

Latest SEC Filings

DateTypeTitle
May 10, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
May 4, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 2, 2022S-8Securities to be offered to employees in employee benefit plans
Mar 1, 202220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
Feb 14, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 14, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 11, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 11, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Nov 9, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Aug 10, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings